Evenity (romosozumab) is a monoclonal antibody designed to treat severe osteoporosis in postmenopausal women who are at high risk for fractures. Osteoporosis weakens bones, making them more susceptible to breaks. Evenity functions by both stimulating new bone formation and reducing bone breakdown, thereby enhancing bone mineral density and strength. Treatment involves monthly administration of two subcutaneous injections (105 mg each) over a 12-month period. Clinical studies have demonstrated that Evenity significantly reduces the risk of vertebral and non-vertebral fractures in women with osteoporosis. Patients should ensure adequate intake of calcium and vitamin D during therapy. It's important to note that Evenity may increase the risk of cardiovascular events; therefore, it should not be initiated in patients who have had a heart attack or stroke within the previous year. Regular monitoring by a healthcare provider is essential during treatment. . Please Note that product description, color, ingredients, package and other information maybe different from the original pack kindly check the product for more accurate details.
